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Abstract:  
 
Aims: Alzheimer’s disease and the transmissible spongiform encephalopathies or 
prion diseases accumulate misfolded and aggregated forms of neuronal cell 
membrane proteins.  Distinctive membrane lesions caused by the accumulation of 
disease-associated prion protein (PrPd) are found in prion disease but morphological 
changes of membranes are not associated with Aβ in Alzheimer’s disease.   
Membrane changes occur in all prion diseases where PrPd is attached to cell 
membranes by a glycosyl-phosphoinositol (GPI) anchor but are absent from 
transgenic mice expressing anchorless PrPd. Here we investigate whether GPI 
membrane attached Aβ may also cause prion-like membrane lesions. Methods: We 
used immunogold electron microscopy to determine the localization and pathology 
of Aβ accumulation in groups of transgenic mice expressing anchored or unanchored 
forms of Aβ or mutated human Alzheimer’s precursor protein. Results:  GPI attached 
Aβ did not replicate the membrane lesions of PrPd. However, as with PrPd in prion 
disease, Aβ peptides derived from each transgenic mouse line initially accumulated 
on morphologically normal neurite membranes, elicited rapid glial recognition and 
neurite Aβ was transferred to attenuated microglial and astrocytic processes. 
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Conclusions: GPI attachment of misfolded membrane proteins is insufficient to cause 
prion-like membrane lesions. Prion disease and murine Aβ amyloidosis both 
accumulate misfolded monomeric or oligomeric membrane proteins that are 
recognised by glial processes and acquire such misfolded proteins prior to their 
accumulation in the extracellular space.  In contrast to prion disease where glial cells 
efficiently endocytose PrPd to endo-lysosomes, activated microglial cells in murine 
Aβ amyloidosis are not as efficient phagocytes.  
 
 
 
 
 
 
Introduction:  
 
Alzheimer’s disease (AD) and the transmissible spongiform encephalopathies or 
prion diseases are progressive neurological disorders in which there is a pathological 
accumulation of a host cell membrane protein. In AD, peptide fragments of the 
Alzheimer’s precursor protein (APP) accumulates in the interstitial spaces as amyloid 
plaques while in prion disease it is a misfolded form of cell-membrane prion protein 
that accumulates as extracellular amyloid fibrils and amyloid plaques. Enzyme 
digestion of membrane spanning APP by membrane secretases leads to formation of 
Aβ1-40 and Aβ1-42 peptide fragments which are released to the extracellular space 
[1,2]. These fragments are assembled into amyloid fibrils which increasingly 
accumulate with age in many species and are particularly abundant as amyloid 
plaques in AD patients. In contrast prion protein is attached to the external leaflet of 
the plasma-membrane by a glycosyl-phosphoinositol (GPI) anchor [3]. Abnormal 
disease associated PrP (PrPd) is a mostly full length form of the normal cell 
membrane protein which has undergone a putative conformational transition into 
an abnormal and pathological isoform [4]. This PrPd may accumulate on membranes 
or be released to the extracellular spaces where it may also aggregate in the form of 
amyloid fibrils or plaques [5,6].   
 
Although extracellular aggregates of PrPd or Aβ fibrils are abundant in brains of 
individuals with prion diseases and AD patients respectively, the precise contribution 
each of these protein aggregates may make towards neurological deficits is unclear. 
Nevertheless both PrPd and Aβ may cause alterations of neuronal membranes which 
may contribute to neuronal dysfunction. GPI anchored PrPd is closely associated with 
a group of highly distinctive morphologic changes in neurite membranes (for review 
see [6]). PrPd monomers or oligomers appear to be poorly internalized from 
neuronal membranes which results in abnormal membrane recycling of a 
ubiquitinated PrPd complex with formation of bizarre coated and spiral membrane 
invaginations, sub-membrane cisterns and excess coated pits [6].  Morphological 
changes of membranes are not reported in AD patients nor are they reported in 
murine transgenic models of Aβ amyloidosis, albeit other studies have suggested 
that oligomeric Aβ aggregates may have molecular effects on membranes leading to A
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alterations to the biophysical structure of the lipid bilayer, ion channels and 
conductivity [7,8,9,10].  
The membrane changes associated with PrPd are found in all species examined 
including mice and in most prion strains [6] with the notable exception of scrapie 
infected transgenic mice expressing anchorless PrP.  A GPI deficient prion protein 
molecule has been generated in a transgenic mouse and in which cellular PrP is not 
retained on the cell membrane [11]. Following infections with a murine adapted 
sheep scrapie prion strain, such mice do not show abnormal membrane changes but 
increased plaques, and cerebral amyloid angiopathy [11]. These data suggest that 
GPI attachment of aggregated or pathological prion protein to membranes may be 
important for generation of morphologic membrane lesions. A GPI anchored Aβ 
molecule has been generated in a transgenic mouse line which is also associated 
with increased plaque formation relative to non-anchored Aβ [12].  
 
In this study we used immuno-electron microscopy to determine whether a GPI 
anchored Aβ peptide would cause morphological membrane lesions similar to those 
observed in prion disease. The results show that GPI membrane linked Aβ does not 
replicate the membrane lesions of PrPd. However, we observed that pathological 
anchored and anchorless Aβ, in common with PrPd of prion diseases, both initially 
accumulate on neurite membranes. Such membrane associated Aβ is rapidly 
recognised by microglia and astrocytes which show corresponding morphologic 
change and acquire these Aβ aggregates of neuritic origin prior to their release and 
aggregation in the extracellular space.  
 
 
Materials and Methods.  
 
Experimental animals:  
 
All mice were kept under specific pathogen-free conditions. The experimental 
procedures were carried out in accordance with the veterinary office regulations of 
Baden-Wurttemberg (Germany) and all experiments were approved by the 
Institutional Animal Care and Use Committees.  
 
Whole brains from eight transgenic mice were perfused fixed with 4% 
paraformaldehyde / 0.1% gluteraldehyde. The transgenes expressed by the mice 
corresponded to co-expression of anchored Aβ and mutant APP at 15 months of age 
(n=2; AβeGPI x APP23); co-expression of anchorless Aβ and mutant APP at 13 
months of age  (n=2; Aβe x APP23 ); co-expression of anchored Aβ and mutant APP 
(n=2; AβeGPI x APP23 ) and expression of a mutant APP alone at 13 months of age 
(n=2 ; APP23). AβeGPI mice express an Aβ1-42 peptide attached to a GPI moiety of the 
PrP protein while Aβe mice release Aβ1-42 without the GPI anchor.  APP23 mice 
express a human APP containing the Swedish mutation (670/671KM-NL).  Further 
details of the generation of these mice and the evidence for increased plaque 
formation in AβeGPI x APP23 mice can be found in Nagarathinam et al. [12]. 
Quantitative assessment of plaque numbers of density was not performed in the A
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present study. J20 mice which over-express double human Swedish and Indiana APP 
mutations (670/671 KM-NL; and 717 V-F) [13] as well as wild-type mice and anchorless 
PrP transgenic mice [11] both of which express full length murine APP, were also 
available as additional positive and negative controls.  
 
 
Methods: 
 
Brains of each mouse were coronally sectioned at 1mm intervals and alternate 1mm 
tissue slices were embedded in paraffin wax. 1mm cubes were sampled from the 
remaining sections to obtain representation of thalamus, hippocampus, cerebral 
cortex and cerebellum, and were embedded in araldite resin.  
 
Immunohistochemistry and immunoblotting  
The light microscopical immunohistochemical procedure was used as described 
previously [14]. 5µm sections were labeled for Aβ1- 42 using antibody AHP677 (AbD 
Serotec, Oxford, UK) at a 1:500 dilution, and for Aβ1-40 using AHP676 (AbD Serotec) 
and ABN 240 (Millipore UK limited, Watford, UK) at 1:500 and 1:100 dilutions 
respectively. Immunolabeling was visualised using the avidin-biotin method (Vector 
Labs, Peterborough, UK) and 3,3′-Diaminobenzidine reaction product. None of these 
antibodies distinguish between the GPI anchored Aβ peptide or Aβ peptides derived 
from the APP23 transgene.   
We further tested the specificity of antibody AHP 676 by dot blotting and Western 
blotting.  AHP676 was unable to discriminate between Aβ1- 40  and  Aβ1- 42 peptides 
(data not shown) .  
  
Light Microscopy procedure – Resin 
The avidin-biotin complex immunohistochemical staining method was applied to the 
etched and pre-treated 1m sections using all Aβ antibodies mentioned above. 
Selected tissue blocks with appropriate immunolabelled areas and control blocks 
were then taken for sub-cellular analysis.  Multiple sections from at least two blocks 
from each brain area were studied from each animal. 
 
Ultrastructural immunohistochemical procedure 
Resin embedded tissue blocks that contained representation of diffuse Aβ labelling 
and Aβ plaques were trimmed to mesas and sections cut at 60nm and labeled as 
described previously [15]. Briefly, sections were taken from resin blocks previously 
found to contain plaques, and were labelled using immunogold methods with 
AHP677 and AHP676 at a 1:10 dilution or ABN 240 at a 1:20 dilution. Labelling was 
maximised by using a formic acid pre-treatment step, however, this compromises 
tissue structure. In the absence of formic acid, tissue structure is optimal though 
some immune signal is lost. Tissue sections were analysed both with and without 
formic acid pretreatment. All illustrations are from non-formic acid treated samples. 
Tissues were also counterstained with uranyl acetate and lead citrate (UA/LC).  
 
In an earlier study Nagarathinum et al [12] showed both by biotinylation and by 
immunofluorescence that the AβeGPI anchored peptide, but not the Aβe unanchored 
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peptide,  reaches  the surface of transfected HEK cells from where it may be  
released by cleavage of the GPI anchors using Phospholipase C. These data confirm 
that the AβeGPI peptide attaches to the cell surface. However, it is important to note 
that the antibodies used do not permit discrimination between peptides produced in 
association with the APP23 allele and the AβeGPI or Aβe alleles. In co-expressing 
mice we cannot therefore be certain whether individual immunogold labeled Aβ 
deposits are anchored or unanchored.    
 
In the previous studies of anchored or anchorless Aβ mice Nagarathinam et al., [12] 
showed that the transgenic AβeGPIxAPP23 line accumulated more Aβ than did the 
transgenic AβexAPP23 line. Measuring the frequency or abundance of products 
using electron microscopy is difficult and requires rigorous stereotactic sampling. We 
did not sample with a view to performing morphometric studies and we made no 
evaluation of the relative amounts of Aβ detected in each model system. Our 
observations therefore provide no judgment on whether the kinetics of  GPI- or GPI+  
Aβ molecular assembly is more or less efficient.  
 
Results:  
 
Aβ antibodies detect only pathological Aβ in transgenic mice.  
 
In the present study we used Aβe and AβeGPI mice intercrossed with APP23 mice. 
While AβeGPI mice express an anchored version of Aβ liberated from a Bri AβeGPI 
precursor protein, Aβe mice liberate from a similar precursor an eight amino-acid 
extended non-anchored Aβ. APP23 mice over-express human APP with the Swedish 
mutation (670/671KM-NL) resulting in an overproduction of human Aβ1-40 and Aβ1-42.  
In previous studies mice expressing anchored or anchorless Aβ peptide displayed no 
plaque accumulations or other plaque associated pathology up to 24months of age. 
However, when such mice were crossed with mutant human APP expressing mice, 
the mice that expressed anchored Aβ peptide showed enhanced plaque pathology 
when compared with mice expressing anchorless Aβ [12].  
 
Each of the Aβ1-40 or Aβ1-42 antibodies (Fig 1 b,c) readily detected plaques both in 
wax or plastic embedded tissue sections. The cores of plaques were more weakly 
labeled than the intensely labeled radiating bundles of amyloid extending from these 
cores (Fig 1a,b,c).  APP23 and double transgenic AβeGPI x APP23 mice showed 
marked Aβ accumulation as amyloid plaques in a primarily cerebro-cortical 
distribution as previously described [16]. J20 mice expressing the double human 
Swedish and Indiana mutations showed a similar distribution of plaques also as 
previously described [16].  
 In addition to plaques, Aβ1-40 or Aβ1-42 antibodies also detected intracytoplasmic 
labelling which in 1µm thick plastic embedded sections presented as granular or 
globular labelling within glial cytoplasm or neuronal cytoplasm. Intraglial labelling 
was most frequently found at the periphery of plaques (Fig 1c) and, although intra-
neuronal labelling was present throughout the cerebral cortex and hippocampus, the 
frequency of intra-neuronal labelling was also considered to be more frequent in 
neuropil surrounding plaques (Fig 1c).   A
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No differences in ultrastructural immunolabelling patterns were observed when 
antibodies to Aβ1-40 were compared with antibodies to Aβ1-42. 
 
No Aβ labelling was detected with Aβ1-40 or Aβ1-42 antibodies in murine APP 
expressing wild-type mice or in anchorless PrP control tissues. Numerous blocks 
taken from brain regions of Aβ transgenic mice that lacked plaques (such as 
thalamus) were also unlabelled. This suggests that the combination of fixation in 
mixed aldehydes and embedding in plastic permits detection of only pathologically 
altered human Aβ by the antibodies used. 
 
 
Aβ is present at three sub-cellular locations in transgenic tissues  
 
In each of the transgenic Aβ mice three types of Aβ accumulation were detected. 
Firstly, fibrillar aggregates of Aβ could be recognized in both immunogold labeled 
and UA/LC stained sections as mature classical amyloid plaques composed of 
variously sized bundles of amyloid fibrils (Fig 2a,b) or as individual small and 
randomly orientated filaments located in the extracellular space (Fig 2e). The latter 
occurred at the periphery of mature plaques and also as apparently immature or as 
nascent plaques.  Secondly, non-fibrillar membrane associated accumulations of Aβ 
(Figs 3,4) were abundant and was found in all transgenic mice irrespective of the 
nature of the transgenic APP mutation or putative presence or absence of GPI 
anchors. Membrane Aβ derived from mutant APP23 and J20 mice may potentially 
occur within membranes while that of GPI anchored Aβ would be expected to occur 
at the exterior surface of the plasma-membrane. The immunogold methods used 
here have an accuracy of approximately 18.5 nm relative to their Aβ molecular target 
[17] and as membranes are 9nm thick we were therefore unable to determine 
whether the membrane topology of Aβ accumulating in APP23, J20 Aβe x APP23 
mice was the same as, or different from AβeGPI x APP23 mice expressing GPI 
anchored Aβ. Thirdly, non-fibrillar intracellular intra-endo-lysosomal Aβ 
accumulations (Fig 5) could be visualized in neurons, astrocytes and microglia using 
immunogold localization methods but were not otherwise appreciable in heavy 
metal stained sections.  
 
Neither membrane associated nor extracellular Aβ is associated with morphologic 
membrane change.  
 
Aβ amyloid plaques had the typical morphological features of these structures as 
previously described in man and rodents [16,18]. Briefly, plaques consisted of dense 
cores composed entirely of closely packed interweaving bundles of amyloid fibrils 
which excluded other cytological elements (Fig 2a) and fibrils were strongly labeled 
with antibodies to both Aβ1-40 (Fig 2b) and Aβ1-42 (Fig
 2e). Bundles of amyloid fibrils 
extended from these cores (Fig 2b) and were surrounded by dystrophic neurites, 
microglial or astrocytic cytoplasm (Fig 2a). Bundles of amyloid fibrils gradually 
attenuated to small clusters of fibrils and finally individual fibrils between neurites 
(Fig 2e).  Microglial cytoplasm was often deeply indented by bundles of amyloid (see A
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Fig 5 a,b). At the margins of plaques, where amyloid fibrils were no longer visible, 
processes and synaptic structures were ensheathed and isolated by microglia or 
astrocytic cytoplasm. Rarely amyloid plaques were found in the meninges (not 
shown) and amyloid fibrils were observed within basement membranes of blood 
vessels (Fig 2 c,d). Neither extracellular bundles of amyloid fibrils nor individual fibrils 
were associated with morphological changes of adjacent neuritic membranes.  
 
Numerous foci of Aβ immunogold labelling were found in areas of neuropil lacking 
bundles or individual amyloid fibrils. Rarely, such foci of Aβ immunolabelling were 
exclusively associated with the membranes of small diameter neurites: small 
dendrites and dendritic spines, small unmyelinated axons and axon terminals (Fig 3a-
e). These occurred in the absence of fibrils or of reactive glial processes or of any 
conspicuous change to the morphology of neuritic membranes (Fig 3a-e). Such foci 
were present in transgenic mice expressing double (J20) (Fig 3 a,b) or single human 
mutations (APP23) of APP (Fig 3c) as well as in mice expressing unanchored (Aβe x 
APP23) (Fig 3 d) or anchored (AβeGPI x APP23) (Fig 3e) forms of Aβ. We interpreted 
this as the first sites and forms of Aβ aggregation or accumulation on or in 
membranes.  
 
Glial cells rapidly recognize and respond to membrane associated Aβ  
 
Some foci of neuritic membrane immunolabelling were additionally associated with 
the presence of numerous thin glial processes interweaving between neurites and 
sometimes encircling individual processes (Fig 4a). These foci were many times more 
numerous than those in which neuritic membrane associated Aβ accumulation was 
confined to neurites alone. Although both astrocytic and microglial processes were 
involved, microglial cells were more conspicuous and more frequent than astrocytic 
processes (Fig 4b) .  Around some neurites the microglial processes that lay between 
them contained the immunogold label while the adjacent neuritic membranes were 
not labeled or showed a low level of labelling  (Fig 4 b,c,d). We consider this 
represents a sequence of pathological processes: the initial event observed by 
immunogold electron microscopy is accumulation of misfolded Aβ on neurites. 
Newly formed misfolded membrane Aβ is recognized quickly by glia, particularly 
microglia which infiltrate and surround Aβ accumulating neurites. A proportion of 
neuritic membrane Aβ is transferred to these contacting microglial or astrocytic 
processes. Similar neuritic membrane and microglial Aβ labelling were also evident 
at the margins of plaques where no amyloid fibrils were evident. No morphologic 
change of membranes was recognized in association with this Aβ accumulation and 
glial infiltration (Fig 4 a-e).  
 
Intra-cellular Aβ is located in lysosomes 
 
Endo-lysosomes of microglia (Fig 5a,b,c,), astrocytes (Fig 5d) and neurons (not 
shown) were labeled for Aβ. Lysosomes containing Aβ were often enlarged (Fig 5c) 
and lysosomes were often more numerous in those microglia that had intracellular 
Aβ.  By electron microscopy examination only a small fraction of neurons showed 
intra-lysosomal labelling (not shown). Similarly, most glial cells did not show A
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evidence of intra-cellular Aβ labelling and where intra-lysosomal labelling was 
observed it occurred in only a fraction of the lysosomes present. Intra-lysosomal 
labelling of microglia was most frequently observed around mature amyloid plaques 
and was not seen in areas where immunolabelling was confined to membranes.  
 
Aβ transgenes have no effect on the sub-cellular locations of Aβ  
 
We were unable to recognize qualitative morphological differences between any of 
the transgenic lines examined.  In each transgenic mouse examined all three 
patterns of amyloid, pre-amyloid (Fig 3a-e) and intracellular Aβ labelling and 
fibrillisation were seen. Similarly early microglial associations with membrane Aβ 
were observed also in each mouse line examined (Fig 4 a-e).  Vascular amyloid was 
identified in all mice including the AβeGPIxAPP23 but was most frequently identified 
in the double APP mutated J20 mouse. Additionally linear accumulations of Aβ 
appearing on larger dendrites (Fig 3b) were also more conspicuous in this mouse.  
 
Discussion: 
 
In none of the four lines of transgenic mice modeling Aβ amyloidosis examined in the 
present study was there evidence of membrane deformation such as is associated 
with PrPd accumulation in prion diseases [6]. As shown previously, compared to the 
co-expressed APP derived Aβ, AβeGPI accounts only for one tenth of the total 
amount of Aβ in the young pre-depositing mice at the age of 2 months [12]. This 
ratio is preserved even after deposition of amyloid plaques at 9 months in the 
double transgenic AβeGPI x APP23 mice and remains on this level. Thus, though 
anchored Aβ cannot be specifically detected by our immunogold labelling, its 
presence can be inferred and therefore the absence of any morphologic changes of 
neuritic membranes seen in AβeGPI x APP23 mice indicates that GPI attachment of 
aggregated peptides is not sufficient to cause morphologic changes of neurite 
plasma-membranes. While we cannot exclude the possibility that more conspicuous 
membrane lesions may have been observed had AβeGPI been present in greater 
abundance, we nevertheless provisionally conclude that properties intrinsic to PrPd 
are necessary to cause increased coated pits, membrane invagination and spiral 
deformation of membranes and that the aggregation of other proteins on or in 
membranes does not invariably result in morphological changes associated with 
dysregulation of endocytosis.  
 
Pre-amyloid forms of Aβ were recognized on membranes in each transgenic mouse 
line. This suggests that peptides formed in AβeGPI x APP23 or Aβe x APP23 mice, as 
well as Aβ peptides arising from single or double mutated human APP, were each 
able to accumulate on or in membranes and that this membrane association 
(putatively membrane assisted aggregation) is a necessary step in the assembly of Aβ 
monomers prior to their release and quaternary organization into fibrils within the 
interstitial spaces. In previous electron microscopy studies of 3xTg-AD mice and aged 
dogs [19],  3D reconstruction of immunolabelled thin sections showed membrane 
associated Aβ arranged in  “sheets and tendrils” on soma and large dendrites 
suggesting a precise linkage of Aβ to other molecular components of dendrosomatic A
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membranes. In agreement with this study we found a significant fraction of pre-
fibrillar Aβ was intimately associated in two dimensions with linear segments of 
plasma-membranes of large dendrites in the J20 mice (Fig 3d).  However, in contrast 
with the observations of Nuntagij et al., [19] we did not find conspicuous linear large 
dendrite associated Aβ accumulation in the APP23 mice or in the anchored or non-
anchored Aβ crosses. In each of these models a significant fraction of membrane Aβ 
accumulation or aggregation was found as individual immunogold label on small 
diameter dendrites, axon terminals and also in lysosomes and in association with 
microglial processes. The reasons for these differences may be technical (different 
antibodies and post-embedding immuno-methods were used) or due to differences 
in the molecular constructs and species of the study subjects.     
 
Since the initial descriptions of microglia surrounding amyloid plaques, the 
microglial-mediated inflammatory response in AD has been extensively studied 
[19,20]. The phenotype of activated microglia in AD and in murine models of Aβ 
amyloidosis are generally considered benign and aimed at clearing damaged tissue 
with minimal further disruption [20,21,22] and microglia are apparently neither 
necessary or sufficient to form or maintain plaques [23]. Microglia in a non-activated 
state, or expressing pro-inflammatory cytokines appear unable to degrade 
internalized Aβ while those experimentally induced to express anti-inflammatory 
cytokines promote degradation in vivo [24,25,26]. It is postulated that microglia may 
contribute to disease progression by failing to switch to an adaptive or anti-
inflammatory response. Results of several studies have suggested that the initial 
immune response, when plaques and tangles are recognized as invading stimuli, may 
be inefficiently followed by an adaptive or anti-inflammatory immune response 
[20,21,27]. The present study provides evidence for an early microglial response 
before release of Aβ to the extracellular space.  
 
Although we did not examine mice at early stages of disease, we can nevertheless 
infer certain stages in the formation of plaques in mice killed at 13 and 15 months of 
age. Aβ was immunolocalised to the membranes of small neurites in the absence of 
any morphological change indicating this to be the earliest stage of pathology we 
could observe in the electron microscope. Foci of membrane associated Aβ 
accumulation also showing infiltration by microglial or astrocyte processes between 
neurites were much more numerous than foci of neurite Aβ accumulation alone. This 
suggests that the initial retention of peptide monomers or small multimers of Aβ 
within the membrane was readily detected by glial cells and in particular microglia. 
Microglia processes in these foci are numerous and often showed increased electron 
density. Some foci showing Aβ within microglial cytoplasm in the absence of neuritic 
membrane Aβ suggests that neurites transfer these initial Aβ deposits from their 
plasma-membranes to microglial and astrocytic processes.  
 
 
Many published AD studies focus on the activation of microglia in response to 
plaques and to fibrillar forms of Aβ. As CNS representatives of the innate immune 
system response, microglia express Toll-like receptors which are able to detect 
microbial and viral pathogens and tissue damage [24, 27]. In AD, Toll-like receptors A
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are thought to be necessary for recognition and clearance of higher weight Aβ 
species. However, Toll-like receptors have evolved to recognize intracellular proteins 
and pathogen associated molecular patterns and it has generally been thought that 
monomeric and oligomeric species of Aβ were not recognized by these receptors. 
We have observed that microglia recognize and show morphologic changes when 
pathologic membrane associated monomeric or oligomeric species of pre-fibrillar Aβ 
are present on neurites. The apparent rapid response of microglia to cell surface Aβ 
is in agreement with imaging studies showing how the processes of so-called resting 
microglia are in continuous motion, constantly monitoring their microenvironment 
and are in contact the surface of all nearby cellular elements every few hours [28].  
The cellular location of plasma-membrane Aβ on microglia are somewhat at variance 
from previous studies in which it has been suggested that soluble Aβ is internalized 
through constitutive non-saturable fluid phase macropinocytosis [29]. In our studies 
we did not see evidence of pinocytosis, rather, in each of the murine transgenics, Aβ 
is apparently passively transferred to microglia plasma-membranes from neuritic 
membranes at these earliest stages of accumulation. GPI anchored proteins are 
capable of passive transfer from one membrane to another [30] as also occurs 
between membranes accumulating PrPd in prion diseases [6,31]. In the present study 
no difference was found for this putative membrane transfer for anchored or non-
anchored Aβ.  
Intracytoplasmic Aβ was observed in a proportion of microglia, particularly those 
surrounding mature plaques. Lysosomal Aβ was found at a very much lower 
frequency than we observed for PrPd in prion disease infected brain [6] where 
lysosomal PrPd is frequently observed in areas of membrane PrPd accumulation 
lacking fibrils [32] . A major difference between prion diseases and the transgenic Aβ 
mice studied above is the protein expression by glial cells. Mouse APP is naturally 
expressed by murine glial cells but AβeGPI, Aβe peptides and human APP transgenes 
are all expressed by the Thy1 promoter [12] and mutant APP in J20 mice is controlled 
by platelet-derived growth factor β [13]. Thus Aβ derived from transgenes will be 
absent or minimally expressed by glia while in prion diseases, prion proteins are 
constitutively expressed by glial cells. The activation of microglia and transfer of PrPd 
to glial cells might therefore be aided by the expression of prion protein at the cell 
surface of glia, but Aβ inhibited from transfer by deficiency of mutant APP on 
microglia and astrocytes. However, microglia that lack prion protein in a transgenic 
line where prion protein was controlled by the glial fibrillary acidic protein promoter 
on a null mouse background, are also capable of taking up PrPd [31]. This suggests 
that the presence of the corresponding normal prion protein or Aβ peptide on 
microglia is not required for the recognition and transfer of misfolded proteins by 
glial cells. We therefore suggest that microglia are not as efficient at internalising 
membrane associated Aβ when compared to membrane PrPd.  
 
In summary, this study has shown that the membrane pathology of prion disease 
was not replicated in the AβeGPI x APP23 mouse, albeit membrane attached forms 
of Aβ are present in low abundance in this mouse, and we therefore suggest that the 
membrane changes seen in prion disease affected tissues are not non-specific 
responses to membrane aggregation of GPI anchored membrane proteins. However, A
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our studies show that the glial responses to neurite membrane protein misfolding 
are similar in both prion disease and murine models of Aβ amyloidosis. In common 
with membrane misfolding associated with PrPd, these studies suggest that microglia 
and also astrocytes recognize and react to Aβ while still present on or in plasma-
membranes and that such recognition are not dependent upon its release to the 
extracellular space or its assembly into quaternary fibrillar structures. Glial cell 
responses to non-fibril membrane forms of pathologic Aβ are irrespective of the 
original APP mutation or of its GPI directed localization on the membrane. As with 
PrPd in prion disease, membrane Aβ appears to physically transfer to membranes of 
microglia but, unlike in prion disease, microglia do not as readily internalize Aβ to 
lysosomes.   
 
 Acknowledgements: MJ, FB and GMcG conceived and designed the study; FB and 
RB carried out animal studies; MJ, GMcG, FB prepared and characterised reagents 
and carried out pathology: MJ wrote the paper with contributions by FB, GMcG, and 
RB. We are grateful to the Gladstone Institute of Neurological disease University of 
California for provision of J20 mice and to Callum Donnelly for skilful technical 
assistance. Roslin Institute is supported by Institute Strategic grant funding from BBSRC.  
 
 
 
Legends for Figures 
 
Figure 1:  Aβ1-40 and Aβ 1-42 antibodies label amyloid plaques and intracellular 
accumulations of Aβ  in plastic embedded tissue blocks.  
 
a) Aβ 1-42  accumulation as amyloid plaques in the cerebrum of an Aβe x APP23 
mouse. Antibody AHP 677. Bar= 200µm. 
b) Higher magnification of (a) showing the cores of plaques have a lower 
labelling intensity as compared with their periphery. Presumed intracellular 
Aβ1-42 in microglia (arrowheads) and neuronal perikaryonal cytoplasm (arrow) 
is infrequently present around this group of plaques. Antibody AHP 677. Bar= 
50µm. 
c) Aβ1-42 accumulation as amyloid plaques in the cerebrum of an AβeGPI x 
APP23 mouse. The plaque also shows lesser intensity of labeling in the core 
and is surrounded by occasional intracytoplasmic microglial (arrowheads) and 
intracytoplasmic neuronal (arrow) Aβ accumulation. Antibody AHP 677. Bar= 
50µm. 
 
Figure 2 : Aβ accumulates as amyloid plaques and extracellular amyloid fibrils in 
transgenic mice expressing mutant APP.  
 
a) Mature plaque from 13 month old AβeGPI x APP23 mouse showing central 
core of dense amyloid surrounded by dystrophic neurites (d). UA/LC Bar = 
5µm 
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b) Aβ1-40 immunogold labeled bundles of amyloid fibrils from the periphery of a 
mature plaques in an APP 23 mouse. Antibody: ABN240, bar = 2µm.  
 
c) Aβ1-40  immunolabelling associated with the basement membranes of a small 
arteriole in a J20 mouse. Antibody: AHP676, bar = 2µm. 
 
d) Aβ1-42  immunolabelling associated with the basement membranes of a small 
arteriole in an APP 23 mouse. Fibrils are just discernable within the basement 
membrane (arrows) . Antibody: AHP677, bar = 2m. 
 
e) Aβe x APP 23 mouse. At the periphery of mature plaques individual fibrils and 
small bundles of fibrils are immunolabelled for Aβ1-42 between viable neurites 
(n) and microglial processes (mg). Antibody: AHP677, bar = 500nm. 
 
Figure 3: Aβ labelling occurs on plasma-membranes of small neurites, including 
terminal axons, that are otherwise morphologically normal and without infiltration 
of glial processes or extracellular amyloid.   
 
a) Aβ1-42 immunogold labelling of the plasma-membranes of small diameter 
neurites in a J20 mouse (axt =axon terminal). Antibody: AHP677, bar = 500nm 
 
b) As above but one process sectioned longitudinally shows labelling along the 
length of the plasma membrane (between arrowheads). Antibody: AHP677, 
bar = 500nm. 
  
c)  APP23 mouse showing Aβ1-40 labelling of the plasma-membrane of an axon 
terminal (axt) containing synaptic vesicles. Antibody: ABN240, bar = 500nm. 
 
d) Aβ1-42 labelling associated with the plasma-membrane of small diameter 
neurites (probable unmyelinated axons and axon terminals) of an  Aβe x 
APP23 mouse.  An un-reactive astrocyte process is also present (as). 
Antibody: AHP677, bar = 500nm. 
 
e)  AβeGPI x APP 23 mouse showing Aβ1-40 labelling associated with axon 
terminal( axt) and other neurite plasma-membranes (arrowheads).  Antibody: 
ABN240, bar = 500nm. 
 
Figure 4: Prominent microglial processes are associated with neurite membrane 
accumulation of Aβ in the absence of extracellular fibrils. 
 
a) J20 mouse showing thin microglial processes (arrows) surrounding and 
isolating morphologically normal neurites. UA/LC, bar = 500nm.  
 
b) APP23 mouse showing prominent Aβ1-40 associated with dark microglial 
cytoplasm (arrows). Aβ1-40 labelling is present both on membranes of neurites 
and microglial processes. Antibody: ABN240, bar = 500nm.  
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c) APP23 mouse showing microglial cytoplasm inserted between neurites. 
Clusters of Aβ1-42 immunolabelling can be visualized in association with   
microglial processes and membranes of neurites. Within some clusters 
individual immunogold label can be seen on neurite membranes   
(arrowheads) and others on microglial processes (arrows). Antibody: AHP677, 
bar = 500nm. 
 
d) AβeGPI x APP23 mouse with a similar field to that shown above. Immunogold 
label for Aβ1-40 is associated with both neurite membranes (arrowheads) and 
thin glial processes running between neurites (arrows). The irregular cross 
sectioned process without organelles (as) is probably an astrocytic process.  
axt: axon terminal; ds dendritic spine. Antibody: ABN240, bar = 500nm. 
 
e) Aβe x APP23. An axon terminal (axt) is associated in approximately half of its 
circumference with Aβ1-42 labelling. The labelling is within the adjacent 
extracellular space where very fine glial processes are just evident (arrow 
heads) and on the limiting plasma membrane. Antibody: AHP677, bar = 
500nm. 
    
Figure 5:  Aβ labelling occurs in a proportion of glial lysosomes. 
 
a) Aβe x APP23 mouse showing bundles of immunogold labeled Aβ1-42 amyloid 
entirely surrounded by microglial cytoplasm. A large irregular lysosome 
(arrow) in adjacent microglial cytoplasm is also labeled for Aβ1-42. Antibody: 
AHP677, bar = 1µm. 
 
b) AβeGPI x APP23 mouse also showing bundles of immunogold labelled Aβ1-40 
engulfed by microglial cytoplasm. A small ovoid endo-lysosome (arrow) in the 
adjacent cytoplasm is also labeled for Aβ1-40. Antibody: ABN240, bar =  1µm. 
 
c) AβeGPI x APP23 anchored mouse with a large lysosome heavily labelled with 
Aβ1-40. The labelling is not uniformly distributed within the lysosome. 
Antibody: ABN240, bar = 1µm. 
 
d) AβeGPI x APP23 anchored mouse showing an astrocyte with three lysosomes 
lightly labeled for Aβ1-42. Antibody: AHP677, bar = 1µm 
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